SCHEMBL4184470

SCHEMBL4184470

COc1ccc(CNc2ncnc3ccc(-c4cccc(CN(C5CC5)S(=O)(=O)c5ccc(Cl)cc5Cl)c4)cc23)c(OC)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 18/20 0.58
CYP1A2 P05177 17/20 0.58
CYP3A4 P08684 17/20 0.58
CYP2C19 P33261 15/20 0.58
CYP2D6 P10635 14/20 0.58
ALDH1A1 P00352 14/20 0.58
CYP2C9 P11712 13/20 0.58
HSD17B10 Q99714 13/20 0.58
TSHR P16473 9/20 0.58
LMNA P02545 13/20 0.56
USP2 O75604 13/20 0.56
MAPK1 P28482 11/20 0.56
HIF1A Q16665 9/20 0.56
ALOX15 P16050 4/20 0.52
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
HPGD P15428 2/20 0.51
KDM4E B2RXH2 1/20 0.51
THRB P10828 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4190949 0.88 CLK4 (0.63) CLK4CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL4182235 0.88 CYP1A2 (0.62) CLK4CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL4180573 0.88 CLK4 (0.66) CLK4CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL4191100 0.86 CLK4 (0.61) CLK4CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL4177366 0.86 CYP1A2 (0.58) CLK4CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL4172100 0.86 CLK4 (0.60) CLK4CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL4178258 0.86 CLK4 (0.63) CLK4CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL4190685 0.85 CYP1A2 (0.62) CLK4CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL4182945 0.85 CLK4 (0.61) CLK4CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL4185543 0.85 CLK4 (0.58) CLK4CYP1A2CYP3A4CYP2C19CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069320-A1 Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof GRUENENTHAL GMBH (DE) 2009-03-12 US claimed
EP-1996562-A1 SUBSTITUTED 4-AMINO-QUINAZOLINE DERIVATIVES AS REGULATORS OF METABOTROPIC GLUTAMATE RECEPTORS AND THEIR USE FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2008-12-03 EP claimed
WO-2007104560-A1 SUBSTITUTED 4-AMINO-QUINAZOLINE DERIVATIVES AS REGULATORS OF METABOTROPIC GLUTAMATE RECEPTORS AND THEIR USE FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2007-09-20 WO claimed
US-20090069320-A1 Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof GRUENENTHAL GMBH (DE) 2009-03-12 US disclosed
EP-1996562-A1 SUBSTITUTED 4-AMINO-QUINAZOLINE DERIVATIVES AS REGULATORS OF METABOTROPIC GLUTAMATE RECEPTORS AND THEIR USE FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2008-12-03 EP disclosed
WO-2007104560-A1 SUBSTITUTED 4-AMINO-QUINAZOLINE DERIVATIVES AS REGULATORS OF METABOTROPIC GLUTAMATE RECEPTORS AND THEIR USE FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069320-A1 Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof GRM1, GRIN1, GRM2 CLK4 3820/4885CYP1A2 4353/4885CYP3A4 4173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.